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THE design of more effective drugs represents the long-term aim in the chemo-
therapy of cancer. In order to improve the performance of the currently available
drugs it is necessary to increase their selectivity of action, and to overcome the
resistance which frequently accompanies their long-term application.
The alkylating agents remain powerful tools in the treatment of malignant
disease, but the factors accounting for selectivity (in terms of those malignancies
which respond best to a given agent) and resistance remain unknown. The cyto-
toxicity of the bifunctional alkylating agents is ascribed to their ability to cross-
link deoxyribonucleic acid (DNA)* (Brookes and Lawley, 1961; Loveless, 1966),
and the resistance of some cells to the action of these compounds has been attri-
buted to their ability to excise the alkylated segment of DNA and repair the
resulting damage (Lawley and Brookes, 1965). Such a mechanism has been
detected in bacterial cells which have been rendered resistant to the action of
alkylating agents (Lawley and Brookes, 1965; Kohn et al., 1965), though there is
little evidence to support this hypothesis in mammalian cells at the present time.
However, an excision process has been demonstrated in HeLa cells following
treatment in vitro with sulphur mustard (Crathorn and Roberts, 1966).
It is feasible that interactions ofalkylating drugs with cytoplasmic components
may to some extent determine their selectivity and contribute to the degree of
resistance offered by the cell to the chemical insult. For example the selective
reduction of the NAD content of the cell sap fraction by alkylating agents (while
not affecting the mitochondrial NAD level) has far-reaching consequences on the
cell's glycolytic ability (Kun et al., 1964). The possibility also exists that direct
alkylation of cytoplasmic protein may occur (Warwick, 1963).
The nucleophilic sulphydryl group is clearly of importance in determining the
metabolism of the alkylating agents, and may be concerned with their detoxica-
tion: the extent to which this group is involved in the mechanisms of action,
selectivity, and resistance has yet to be determined. It has been shown that
alkylating agents react in vivo with sulphydryl-containing compounds (Warwick,
1963), while a reduction in the level of leucocyte glutathione occurred in chronic
* The following abbreviations will be used throughout this paper: DNA-deoxyribonucleic acid;
RNA-ribonucleic acid; DTNB-5,5'-dithiobis(2-nitrobenzoic acid); GSH-reduced glutathione;
GSSG-oxidised glutathione; Met-methionine; CySH-cysteine; CySSCy-cystine; HCySH
homocysteine; HCySSCy-homocystine; Glu-glutamic acid; Gly-glycine; N-Val-norvaline;
NAD-nicotinamide adenine dinucleotide; EDTA-ethylene diamine tetracetic acid.ALKYLATING DRUGS: SELECTIVITY AND RESISTANCE
granulocytic leukaemia following the administration of Myleran (Harrap and
Speed, 1964). Thiol-containing compounds have been used to mitigate the toxic
effects of alkylating agents (Therkelsen, 1958, 1961; Connors et al., 1965). Some
authors have demonstrated an increase in the non-protein sulphydryl content of
nitrogen mustard-resistant Yoshida sarcomata (Hirono, 1961; Hirono et al., 1962;
Ball et al., 1966). Furthermore, the sensitivity ofa tumour to chemotherapy with
alkylating agents may be associated with the ratio protein bound: protein free
sulphydryl groups, since in arange oftransplantable tumours ofvarying sensitivity
to alkylating agents, the more resistant tumours possessed a higher ratio of
protein-free to protein-bound thiol (Calcutt and Connors, 1963).
An assessment of this evidence suggests that interaction between alkylating
agents and thiol-containing components of the cytoplasm may have some rele-
vance to resistance and selectivity of action. A suitable experimental model
would be provided by the interaction of a series of clinically-important com-
pounds with a drug-sensitive line of an experimental tumour, and with a subline
exhibiting acquired resistance to these agents. We have chosen the Yoshida
ascites sarcoma in drug-sensitive and resistant forms (Ujhazy and Winkler, 1965)
and busulphan, chlorambucil and melphalan for detailed study. These drugs
have important clinical applications in the treatment ofmyeloproliferative disease,
lymphoproliferative disease and myelomatosis, respectively (Medical Research
Council's working party report, 1968; Boesen et al., 1964; Rundles, 1967).
Based on melphalan the order of resistance of the drug-refractory cell line in
the present work was approximately 300 times that ofthe sensitive line. For the
other two drugs the refractory line was ten times more resistant than the sensitive
line.
We have restricted our attention to the levels of glutathione and the sub-
strates responsible for synthesis of this tripeptide, and have related the changes
observed to the accompanying alterations in nucleic acid and protein content.
The work will be presented in two sections, I, II, relating to the two discrete
dose levels selected for study (see Material and Methods).
MATERIAL AND METHODS
Drugs: Leukeran (chlorambucil) (CICH2CH2)2N.C6H4(CH2)3COOH, Myleran
(busulphan) CH3SO20(CH2)40S02CH3, and Alkeran (melphalan) (C1CH2CH2)2N.
C6H4CH2CHNH2COOH were synthesised intheChester Beatty ResearchInstitute.
They were administered at two dose levels: I " curative ", II " therapeutically
ineffective ". In the latter case 95% of the sensitive cells survived treatment.
The growth rate of resistant cells was unaltered at either dose level (Harrap and
Hill, 1969). All drugs were administered subcutaneously, on the fifth day
following tumour transplantation in a single dose. The doses employed are
listed in Table I, and full details of the animal experimentation are provided in
TABLE I.-Drug Do8e8 Adminiatered
Dose (mg./kg. body weight)
"Therapeutically
Drug "Curative" ineffective"
Chlorambucil . 8 1 5
Melphalan . 2 0 016 or 0 16
Myleran . 20 4 0
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the following paper (Harrap and Hill, 1969). In this study female Wistar rats of
the Chester Beatty strain were used at 6 weeks of age (body weight approx.
200 g.).
Reagent chemicals were obtained from Hopkin and Williams Ltd. or British
Drug Houses Ltd., AnalaR grades being used where available. Amino acids were
purchased from British Drug Houses Ltd. and thiodiglycol from Sherman Chemi-
cals. Oxidised and reduced forms of glutathione were purchased from Sigma
Chemical Co.
Metabolic studies
At intervals following drug administration, animals were killed by cervical
dislocation, in groups of three, from " resistant control ", " resistant treated ",
" sensitive control " or " sensitive treated " groups, and the peritoneal contents
aspirated with ice-cold 0*3% saline: all subsequent preparative manipulations
were conducted at 0° C. The cells were collected by centrifugation at 350 g and
0-4° C. for 10 minutes, and any erythrocytes remaining in the pellet were removed
by " osmotic shock " (Walton et al., 1957). The tumour cells were then washed
in isotonic saline, resuspended to a known volume in isotonic saline (to yield the
" tumour-cell preparation ", and counted in an electronic particle counter (Model
A, Coulter Electronics, Kenmore, Chicago) with threshold and aperture current
settings 15 and 2 respectively.
DNA, RNA, andprotein estimations
Cells were removed by centrifugation from aliquots of the " tumour cell
preparation ", and stored for up to 48 hours at 0-4° C. before extraction with
perchloric acid by the method of Volkin and Cohn (1954). DNA was estimated
according to Burton (1956), RNA by u.v. absorption, or by the orcinol procedure
(Brown, 1946), and protein according to Lowry et al. (1951).
Protein-free thiol and disuiphide levels
Aliquots of the " tumour-cell preparation " were centrifuged at 350 g for
10 minutes, and the resultant pellet deproteinised and assayed for acid-soluble
sulphydryl compounds according to a modification of the Ellman colorimetric
procedure (Harrap, 1967; Ellman, 1959). Electrolytic reduction (Dohan and
Woodward, 1939), of a second aliquot of the supernatant from deproteinised cells,
followed by colorimetric assay yielded the " total soluble thiol " content.
"Sulphur amino-acidpool "
This was defined to contain glutathione (oxidised and reduced), cysteine,
cystine, homocysteine, homocystine, methionine, glutamic acid, and glycine.
Quantitative assay ofthe content ofthese amino acids in tumour cells was carried
out using the " Technicon Amino-Acid Autoanalyser " (Technicon Instruments
Co. Ltd., Chertsey, England). The instrumental technique was according to
Hamilton's modification (1963) of the procedure of Spackman et al. (1968), and
in our hands was operated according to the recommendations of Boulter (1966).
Cell pellets obtained by centrifugation of aliquots of " tumour cell preparation"
were deproteinised with ice-cold 9% aqueous trichloroacetic acid in a Potter-
Elvehjem homogeniser, and the suspension centrifuged at 1200 g for 20 minutes.
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The clear supernatants were stored at 0-40, before analysis, for periods not
exceeding one month, and during this time storage artifacts were negligible. The
supernatants were extracted four times with equivalent volumes of ether,
evaporated to dryness, in vacuo, and finally dissolved in 1 ml. of " internal stan-
dard solution " and adjusted to pH 2%0 with 6NHCI. The " internal standard
solution " contained 0-2 ,umole L-norvaline per ml. (ninhydrin positive) and
0*2 ,umole thioglycollic acid per ml. (DTNB positive). The Autograd was set up
as follows:
Chamber Solutions used
1 70 ml. buffer pH 2 7, 5.0 ml. methanol
2 72 ml. 3,, ml.
3 75 ml.
4 25 ml. ,, ,, ,, 50 ml. buffer pH 4 0
5 70 ml. ,, ,, 4 0 5-0 ml. buffer pH 540
6 6 ml. ,, ,, ,, 940 ml. buffer pH 4 0, 60 ml. buffer pH 5 0
7 75 ml. ,, ,, 5.0
8 ,. .. . .
9 ,. .. .
Buffers were prepared according to Schmidt (1966), except that thiodiglycol was
omitted from all the Autograd buffers, and was only added to the pH 2.7 buffer
used for washing the column between analyses. In this way it was possible to
prevent oxidation of sulphydryl-containing compounds, while containing the
extent of the blank reaction with DTNB. The column was eluted at a rate of
0.5 ml./minute, and the effluent was split into three fractions as follows: (i) 0-16 ml.
for c-amino group estimation, following reaction with 0-42 ml. ninhydrin/hydrin-
dantin and recording the optical density at 570 m,1; (ii) 0*16 ml. was mixed with
0.32 ml. of DTNB reagent (0.5 x 10-3M, 10-3M with respect to EDTA), and the
optical density recorded at 410 m,a; (iii) the remaining eluate was pumped to a
fraction collector, and fractions accumulating over a 10-minute interval were
collected in order to check the identity of the materials eluted from the column.
These fractions were desalted electrolytically or by an ion-exchange method
(Smith, 1958), evaporated to dryness, dissolved in 10% aqueous isopropanol, and
stood with an equal volume of 0.25 M N-ethyl maleimide in isopropanol for
30 minutes. Aliquots of this material were then submitted to high-voltage paper
electrophoresis or paper chromatography, or to the successive two-dimensional
combination of both these techniques.
High voltage electrophoresis
Locarte two-dimensional high-voltage electrophoresis equipment, Model
HVPT/5, 3 MM paper, M formic acid/M acetic acid buffer, pH 2-0: 8 kv for 1 hour.
Paper chromatography
Descending chromatography was carried out on Whatman 3 MM, or No. 1
paper in: n-butanol (120 vol.); glacial acetic acid (30 vol.); water (50 vol.), for
16 hours. Colour development was with ninhydrin (0.2% in acetone). Fig. 1
illustrates a typical elution pattern obtained following the separation ofa mixture
of the constituents of the " sulphur amino-acid pool " in the Autoanalyser, and
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Fig. 2 indicates the extent tq which these components were separable by two-
dimensional chromatography and electrophoresis.
Subcellularfractionation
Cells were removed from an aliquot of the " tumour cell suspension " by
centrifugation at 350 g, and resuspended in sucrose solution (final molarity 0.34).
This cell suspension was then admitted to, and expelled from a 10 ml. syringe,
through aNo. 20 gauge needle (Gillette 25 g x i), until phase contrast microscopy
demonstrated the absence of intact cells (six passages at 40 C.). The sucrose
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FIG. l.-Elution of a mixture of the components of the "sulphur amino a-cid pool" from the Auto-
analyser: continuous line represents E1670, discontinuous line E14-1.
concentration ofthe cell lysate was then adjusted to 0. 25 M, nuclei and cell debris
collected at 3000 g, and washed once with 0-25 M sucrose. The resulting prepara-
tion of nuclei was substantially free of debris and intact cells (assessed following
May Grunwald-Giemsa staining). Mitochondrial and microsomal fractions were
collected after centrifugation and washing at 24,000 g (30 minutes) and 100,000 g
(30 minutes) respectively.
RESULTS
Section I: " curative do8e "
The variation in content of DNA, RNA, protein, and glutathione in sensitive
and resistant tumour cells, between 5 and 8 days following tumour implantation,
is shown in Table II. No significant change in any of these properties occurred
with time: when the observations over the 4-day period were grouped as a whole,
then the higher contents of RNA and protein in the sensitive cells were found to
be very significant (P > 0.001). Levels ofthose components ofthe sulphur-amino
acid pool which were detectable are listed in Table III. Good agreement was
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FIG. 2.-Two dimensional electrophoretogram-chromatogram of a mixture of the components of the
" sulphur amino acid pool ".
TABLE II.-Comparison of DNA, RNA, Protein and Glutathione
Sensitive and Resistant Yoshida Ascites Cells
Tumour DNA RNA Protein
Tumour age (mg./109 (mg./109 (mg./109 (b
sample (days) cells) cells) cells) 1C
Sensitive . 5 . 13-0 . 35 6 . 156
6 . 11*6 . 35*9 . 137
7 . 122 . 36-1 . 147
8 . 12-9 33-1 . 138
Mean . 124 . 35.3 . 145
(st. error) . (0 2) . (0 6) . (3)
Resistant 5
6
7
8
Mean
(st. error)
12*2
12*4
11*3
10*8
11*8
(0 3)
29*6
28* 1
26 3
26*2
26*8
(1.0)
115
105
105
106
106
(3)
Contents of
GSH
umoles/
09 cells)
6* 7
6*5
6*6
6-2
6*5
(0*3)
7.7
7-4
6*9
6*8
7*0
(0*1)
IN
HC t;,
;;ySflw.
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obtained between the Autoanalyser and manual estimations ofGSH (cf. Table II).
The differences in level ofGlu and Gly in the two cell strains were highly significant
(P > 0.001).
TABLE III.-Comparison of the " Sulphur Amino Acid Pool " Content ofSensitive
and Resistant Yoshida Ascites Cells
Tumour Compounds detected ,umoles/109 cells
Tumour age A
sample (days) GSH Glu Gly CySSCy Met.
Sensitive . 5 . 7-2 7-9 7-1 0-3
6 . 7 0 8-3 6 8 0.5
7 . 6-2 9 3 7-2 0- 3
Mean . 6-8 8-5 7 0 0 4
(st. error) . (0.3) (0 4) (0 2) (0 1)
Resistant . 5 . 8 4 4- 5 2 * 9 0 2
6 . 7-8 4-1 2-7
7 . 6-7 4 0 2-8 0 4 0 05
Mean . 7-6 4-2 2-8 0 3
(st. error) . (0 5) (0 2) (0 1) (0 1)
The two cell strains responded quite differently to treatment with alkylating
agents, and chlorambucil, melphalan and Myleran induced an increased level of
DNA, RNA and protein in the sensitive cells, while little accumulation of these
materials occurred in the resistant cells. The effects on DNA are plotted in
Fig. 3, and it is clear that each ofthe three drugs exhibited quantitative differences
from the other two. With Myleran and melphalan, a drop in DNA content
occurred over the first 5-8 hours in the sensitive cells, followed by a progressive
rise, so that by 75 hours the DNA content per cell had almost doubled. On the
other hand, the DNA content of chlorambucil-treated sensitive cells had almost
doubled by 12 hours, then falling to approximately two-thirds of this value by
26 MYLERAN 2L MELPHALAN 24 CHLORAMBUCIL
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FIG. 3.-DNA content of Yoshida ascites sarcoma cells following " curative" chemotherapy.
09 " sensitive " control; A, " resistant " control; * *, " sensitive " treated;
A A A, " resistant " treated. The overall scatter about any point : 20%. Each
point represents the mean of three determinations.ALKYLATING DRUGS: SELECTIVITY AND RESISTANCE
24 hours, after which a more gradual rise occurred. Although the three drugs did
induce small changes in the resistant cells, these could be ignored in comparison
with the effects just described.
Myleran and melphalan had similar effects on the RNA content of sensitive
cells (cf. Fig. 4), and the level rose in each case from the value at 12 hours after
treatment, the initial rate being three times as fast with melphalan, compared
with Myleran: with both drugs the RNA content had approximately doubled by
80 hours. In the case of chlorambucil, the RNA content had increased 2-fold
at 12 hours, but had returned to control values at 24 hours, when a second, slower
increase occurred, so that a doubling in RNA content per cell was achieved by
80 - MYLERAN 80 - MELPHALAN 80 - CHLORAMBOUCIL
60 60 60
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FiG. 4.-RNA content of Yoshida ascites sarcoma cells following " curative" chemotherapy.
O, " sensitive " control; A, " resistant " control; * 0 *, "sensitive " treated;
A A *, " resistant " treated. The overall scatter about any point >20%. Each
point represents the mean of three determinations.
50 hours. For each drug, these events were reflected, at a lower level, in similar
changes in the resistant cells: in each case the RNA content ofthese cells returned
to " control " values.
Changes in protein content occurring after drug treatment are illustrated in
Fig. 5. Protein accumulated in the sensitive cells, though the pattern was quite
different from drug to drug: whereas with melphalan an immediate and continuous
increase occurred, with Myleran the elevation was delayed for 24 hours following
treatment. Following the administration of chlorambucil, protein commenced
to accumulate immediately, though a plateau level was maintained between 12
and 28 hours, after which synthesis recommenced. The increase in protein
content 54 hours after treatment with Myleran, melphalan or chlorambucil was
2-fold, 3-fold, or 2-fold, respectively. Relatively insignificant changes took
place in the resistant cells.
The acid-soluble thiol content of the cells was also modified after treatment
with each ofthe alkylating agents (cf. Fig. 6): commencing 24 hours after Myleran
or melphalan treatment, the reduced glutathione content of the sensitive cells
progressively increased, until by 60 hours the value had increased 4-fold. With
both drugs, a 25% increase in the glutathione content of the resistant cells had
occurred-either at 12 hours after melphalan injection, or at 28 hours after
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Myleran administration. The response to chlorambucil was quite different.
Following an initial fall in level, the glutathione content of the sensitive cells
doubled by 12 hours and then fell back to control levels by 24 hours, after which a
progressive increase occurred similar to that found with Myleran and melphalan.
At 60 hours the glutathione content ofthese cells had increased more than 4-fold.
In resistant cells from animals receiving the same dose of chlorambucil, the gluta-
thione level reached approximately halfthat ofthe sensitive cells at 12 hours, and
returned to the control value at 24 hours. However, in this case, the level
decreased, subsequently reaching half the control value by 60 hours.
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FIG. 5. Protein content ofYoshida ascites sarcoma cellsfollowing " curative "chemotherapy.
0, " sensitive " control; A, " resistant " control; * * 0, "sensitive" treated;
* A A, "resistant" treated. The overall scatter at any point t 20%. Each
point represents the mean of three determinations.
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FIG. 6. Variation in content of reduced glutathione (GSH) following " curative" chemo-
therapy. 0, " sensitive " control; A, " resistant " control; * * , "sensitive "
treated; A A A, " resistant " treated. The overall scatter about any point was >.20%. Each point represents the mean ofthree determinations.ALKYLATING DRUGS: SELECTIVITY AND RESISTANCE
Only after chlorambucil treatment could oxidised glutathione be detected: it
appeared early in sensitive cells, though synthesis was delayed in resistant cells
(Fig. 7). No oxidised glutathione was detected after treatment with Myleran or
melphalan.
With the exception ofglutathione, chemotherapy withMyleran or chlorambucil
resulted in marginal alterations in the composition of the " sulphur amino-acid
pool " (Table IV). Although the levels ofglutamic acid andglycine were modified
following treatment with chlorambucil or Myleran, yet the content ofthese amino
acids in the sensitive cells still exceeded that of the resistant cells.
20
15
10
20 40 60 80
TIME (hrs) after injection
FIG. 7.-Appearance of oxidised glutathione following " curative" chlorambucil treatment.
* * *, sensitive cells; A A A, resistant cells. The overall scatter about
each point zf 10%. Each point represents the mean of three determinations. No oxidised
glutathione was detected in either cell strain prior to treatment.
Subcellular fractionation of sensitive cells which had been isolated from
animals 52 hours after chlorambucil treatment, revealed that the increase in
glutathione occurred predominantly in the cell supernatant fraction (Table V).
Changes in cell volume accompanied the interaction ofthese alkylating agents
with the sensitive cells: these findings have been outlined in the following paper
(Harrap and Hill, 1969).
Section II: " therapeutically ineffective dose"
In Fig. 8 are plotted the levels ofglutathione in sensitive and resistant cells at
various times following the administration of drug. In all cases the glutathione
content of the sensitive cells increased, the peak level occurring at 28, 36 and
54 hours for Myleran, melphalan and chlorambucil respectively. This peak level
ofglutathione corresponded to a 2-fold increase over the control value in the cases
of Myleran and chlorambucil, but with melphalan (dose 0-016 mg./kg.), only a
50% increase was detected. WVhen the melphalan dose was increased 10-fold, then
GSH increases were comparable to those found for the other two drugs. The
explanation for this discrepancy lay in a 10-fold loss in sensitivity to alkylating
agents of the sensitive strain, which had occurred after the Myleran and chloram-
bucil studies were completed andbefore these melphalan experiments were started.
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TABLE IV.-COmparison of the " Sulphur Amino-Acid Pool " Content ofSensitive
and Resistant Yoshida Ascites Cells Following " Curative " Chemotherapy
Tumour
sample
CHLORAMBUCIL
Sensitive
Resistant
MYLERAN
Sensitive
Resistant
Hrs after
injection
4
8
13
28
55
Mean
(st. error)
4
8
13
28
55
Mean
(st. error)
4
8
29
52
77
Mean
(st. error)
4
8
29
52
77
Mean
(st. error)
Compounds detected utmoles/IO9 cells
Glu Gly CySSCy Met.
6*7
6*6
7-8
6-3
7.5
7 0
(0 2)
3-7
4.3
4*2
5 0
5*0
4.4
(0 3)
8-1
7-6
8*1
10X0
10.0
8 7
(0.9)
2 7
2-3
3-8
4 6
4 1
3.5
(0 4)
4.7
5.3
6*6
5*6
6*0
5-6
(0-4)
3-8
3 6
3 9
3.5
3.9
3.7
(0.2)
7*1
6*3
5.7
5 6
4.9
5.9
(0.4)
3-3
4-0
3.3
3.1
3.4
3.4
(0.2)
0-2
0 3
0*3
0*2
0-2
0 2
(0.03)
0 3
0 4
0*1
0-1
0.1
0-2
(0.06)
0-2
0*2
0 3
0-2
(0.04)
0 03
0 04
0 04
0*04
(0.01)
0-03
0-02
0-01
0-02
(0.01)
0*05
TABLE V.-Subcellular Distribution of Glutathione in Sensitive Yoshida Ascites
Sarcoma Cellsfrom " Control " and Chlorambucil Treated (Curative Dose) Animals,
Expressed in fimoles per 109 Cells
GSH ,Amoles/109
cells
Sensitive controls
Sensitive treated
Nuclear
fraction
0*5
0 7
Mitochondrial
fraction
0*3
0-5
Cell sap
4-9
19 6
Microsomal
fraction
0-1
0-1
However, at this time the sensitive cells were still 30 times more sensitive to
melphalan than the resistant cells. At no time was GSSG detected, and the level
of GSH in the resistant cells remained unaltered after drug treatment.
The RNA content of the sensitive cells increased by 36-67%, peak values
occurring at 28 hours, 36 hours and 54 hours forMyleran, melphalan, and chloram-
bucil respectively (Fig. 9). No RNA changes were detected in the resistant cells.
The changes in protein content are shown in Fig. 10. Increases of 37-67%
were observed in the sensitive cells, and the maxima were located at 28, 36 and
54 hours for Myleran, melphalan and chlorambucil respectively. No change was
noted in the protein content ofthe resistant cells. No DNA changes were detected
in either cell strain.
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FIG. 8.-GSH content of Yoshida ascites sarcoma cells following " low dose " chemotherapy:
0,sensitivecontrol; A,resistantcontrol; * * *,sensitivetreated; A A A
resistant treated. The overall scatter about each point 4i. 10%-,. Each point represents the
mean of three determinations.
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FIG. 9.-RNA content of Yoshida ascites sarcoma cells following " low dose " chemotherapy:
0,sensitive control; A,resistant control; 0 * 0, sensitive treated; A A A,
resistant treated. The overall scatter about each point :. 10%. Each point represents
the mean of three determinations.
At this dose level the drugs elicited a maximum increase in cell volume of 50%
(Harrap and Hill, 1969).
DISCUSSION
Section I: " curative dose "
This part ofthe study has revealed that the content ofprotein, RNA, glutamic
acid, and glycine in the sensitive tumour cells was significantly higher than that
of the resistant cells (before treatment with alkylating agents). The elevated
amino acid levels do not imply necessarily a greater potenial for glutathione
synthesis in the sensitive cells, since in this respect the concentration of cysteine
would appear to represent thelimiting substrate factor (Jackson, 1968): no cysteine
was detected in either cell strain, and the levels of methionine and cystine were
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FIG. 10.-Protein content of Yoshida ascites sarcoma cells following "low dose" chemo-
therapy: 0, sensitive control; A, resistant control; * 0 0 sensitive treated;
A A A, resistant treated. The overall scatter about each point 1t 10%. Each
point represents the mean of three determinations.
comparable. It is not known whether any particular component of the protein
fraction was elevated in the sensitive cells, though other experiments have indi-
cated that these contained twice as much y-glutamylcysteine synthetase (EC
6.3.2.2.) as resistant cells (Harrap et al., 1968).
Drug-induced increase in the nucleic acid, protein, and glutathione content of
the sensitive cells occurred in two discrete phases: 0-24 hours, and post-24 hours
respectively. These biochemical changes may be a counterpart of the altered
growth-rate of the tumour cells resulting from treatment with the individual
drugs.
During the 0-24-hour period following chlorambucil treatment the sensitive
cells continued in logarithmic growth, while with Myleran the rate ofproliferation
decreased; on the other hand, treatment with melphalanresulted inthe appearance
of a plateau in the growth curve (Harrap and Hill, 1969). Hence, administration
of Myleran and melphalan reduced the growth rate of sensitive cells during the
24 hours immediately following treatment, whereas the effects of chlorambucil
were not apparent until 24 hours after the drug was given. This related behaviour
of Myleran and melphalan, as distinct from chlorambucil, was endorsed by the
accompanying biochemical changes: the pattern ofnucleic acid, protein and gluta-
thione increase in Myleran and melphalan-treated sensitive cells was broadly
similar, but differed from that induced by chlorambucil (though certain quantita-
tive differences from drug to drug were nevertheless detectable).
During the post-24 hour period, each drug induced comparable changes in the
components studied. Extensive tumour cell death was occurring, and the bio-
chemical changes observed must have represented the altered metabolism of
lethally-damaged (yet living) cells. (It was important to recognise that drug-
treated cells harvested throughout the course of these experiments were not dead
cells-they continued to synthesise protein and nucleic acid-though they could
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not divide.) Other reports have suggested that DNA synthesis can be influenced
by these agents without impairment of RNA or protein synthesis: the effects of
alkylating agents onthe content andsynthesis ofDNAinbacterial andmammalian
cells have been reviewed recently by Ochoa and Hirschberg (1967).
The increases in glutathione levels which resulted from drug administration
were at least two orders ofmagnitude greater, on a molar basis, than the amount
of drug which could enter the cells (assuming a uniform distribution of the agent
throughout the animal). Therefore, it seemed likely that the changes in gluta-
thione content must have possessed a more sophisticated origin than replacement-
synthesis of drug-alkylated thiol. The possibility that the increased level could
be attributed to an accumulation of glutathione precursors has been eliminated
in the present study. Furthermore, the appearance of oxidised glutathione in
response to chlorambucil-treatment underlined the involvement ofthis drug with
glutathione metabolism: the fact that peak levels occurred at different times
(dependent on the cell strain) suggested that this drug may have selectively
different effects on the glutathione oxido-reduction system of the cells. This
possibility is being examined at the present time. In addition, the preliminary
rise in glutathione content of the sensitive cells, which reached peak values at
12 hours after treatment with chlorambucil, may represent a selective mechanism
for the inactivation ofthis drug (such an effect was not observed with Myleran or
melphalan).
Drug treatment produced an increased protein content in the sensitive cells
which paralleled a rise in cell volume (reported in the following paper (Harrap and
Hill, 1969): presumably the dimensions ofthe cells increased in order to accommo-
date this elevated level of protein. However, the drug-induced increase in
glutathione level could not be entirely associated with these events, for while the
cell volume had doubled (at 60 hours) the glutathione content quadrupled.
The quantitative differences in response between sensitive and resistant cells
could not be accounted for by selective differences in drug uptake: in vitro experi-
ments have demonstrated that both cell strains accumulated comparable amounts
ofdrug (Harrap and Hill, unpublished results).
The biological reactivity of these alkylating agents must be determined by
competition between the rates of drug inactivation and DNA alkylation. It has
been demonstrated that chlorambucil could mobilise a nucleophilic cell constituent
(glutathione) before the effects of DNA alkylation had been observed, thus
increasing t4e number of alkylating sites available to the drug. Myleran and
melphalan could not mobilise GSH within this 24-hour period. These findings
imply variations in the mechanism ofdetoxication ofthe drugs. Such differences
may appear surprising in view of the similarities in structure and half-life of
hydrolysis of chlorambucil and melphalan. However, in vitro experiments have
demonstrated that the alkylating abilities ofthese two drugs differ markedly once
they have been absorbed by the cells (Harrap and Hill, unpublished results).
This suggests that in addition to loss of drug by alkylating side reactions, these
agents may also be sequestered in an active form, possibly by protein. This
speculation is supported by the observations ofWade et at. (1967).
The metabolic response of the cells to chlorambucil was clearly faster than to
Myleran and melphalan (the reverse of the biological response) and it becomes
important to determine the rate at which these drugs selectively alkylate DNA in
order to assess the relative importance ofthe biochemical events described here.
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Section II: " therapeutically ineffective dose "
It could be argued that the metabolic alterations discussed above were
impressed onthe cells by alkylated DNA, and thatthe changes reflected the altered
function of lethally damaged genetic material. It was necessary to investigate
this possibility, and to examine to what extent the changes were representative of
the interaction ofthe alkylating agents with cellular components. This objective
was achieved by examining the alterations produced by " therapeutically
ineffective " doses of the drugs, from which the sensitive cells would recover.
Under this circumstance the observed biochemical changes could not be ascribed
to metabolic irregularities arising from the lethal alkylation of DNA.
A reversible accumulation of RNA, protein and GSH occurred in the sensitive
cells, though the DNA content remained unaltered: no changes were observed in
the levels of these compounds in the resistant cells. These effects should be
compared with the irreversible accumulation ofDNA, RNA, protein, and GSH in
sensitive cells following the administration of " curative " doses of the agents.
Again the cell volume increased presumably in order to accommodate the
raised level ofRNA and protein. The accompanying rise in GSH, as with curative
drug doses occurred in greater proportion to the cell volume increase, and probably
was not associated with the increase in protein and RNA content. This point
may be amplified by reference to Table VI: fractionated doses of melphalan
TABLE VI.-Effect of "Fractionated " Doses of Melphalan on GSH, RNA, Protein
Content ofSensitive Yoshida Ascites Cells
GSH RNA Protein
(Ikmoles/10' (mg./109 (mg./109
cells) cells) cells)
increase increase increase
Dose (mg./kg.) (%) (%) (%)
0 .6 .39 .120
0 016 . 8.5 42 . 46X0 18 . 152 27
0X16 . 13X2 112 . 4857 25 . 177 47
produced much larger effects on the GSH content of sensitive cells than on their
protein or RNA contents. If the effects elicited by a dose of 0-16 mg./kg. were
related to a bapeline of 0.016 mg./kg., then for this 10-fold increase in dose, the
rise in GSH was approximately four times the protein, and nine times the RNA
elevation.
The evidence discussed in the two sections above implies that-these drugs
disturb the metabolism of several cellular constituents, namely:
(i) DNA
(ii) RNA and protein
(iii) GSH.
(i) Curative doses ofdrug resulted in an accumulation ofDNA, while the DNA
content remained unchanged following low (therapeutically ineffective) doses.
(ii) An irreversible accumulation of RNA and protein occurred (paralleled by a
corresponding change in cell volume) following curative doses, while the low doses
yielded reversible increases in these components (again with a corresponding
change in cell volume). (iii) Drug-induced increase in glutathione content was
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always considerably greater than the changes observed in any other component at
either dose level.
Although broad similarities were detected in the pattern ofresponse to ineffec-
tive doses of each drug, the reversible changes observed were separable from drug
to drug in terms of their time and duration of onset, indicating a measure of
individuality of action. It is interesting that the order of reactivity of these
drugs, as measured here by the time of peak accumulation of the various compo-
nents, correlated well with their effectiveness (at " curative dose " levels) on the
tumour growth rate (Harrap and Hill, 1969), and again was the inverse of the
chemical reactivities of the agents.
SUMMARY
A strain ofthe Yoshida ascites sarcoma which responded to chemotherapy with
alkylating agents contained elevated levels of RNA, protein, glutamic acid and
glycine, when compared with a drug-resistant strain. Curative treatment with
individual alkylating agents resulted in the accumulation of DNA, RNA, protein
and GSH in the sensitive cells. These reactions occurred during two time
intervals: 0-24 hours and post-24 hours. Events occurring during the second
period were broadly similar, irrespective ofthe identity of the drug used, while in
the first period each drug elicited qualitatively and quantitatively different
effects. In all cases the relative increase in glutathione content was greater than
that of the other components measured.
A reversible accumulation of glutathione, RNA and protein occurred in the
sensitive cells following the administration, to the host rats, of therapeutically
ineffective doses of a number of alkylating drugs. The time course of these
changes differed according to the identity of the drug used, and provided a
measure of the selectively different action of the latter on the cells. Similar
effects were not observed in a resistant strain of cells.
It is proposed that alkylating agents may have independent effects on several
cellular constituents: DNA, RNA and protein; glutathione.
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